Insulin aspart biosimilar (Kunpeng)

门冬胰岛素生物类似药（鲲鹏生物）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameInsulin aspart biosimilar (Kunpeng)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNingbo Kunpeng Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNingbo Kunpeng Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A